Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | RELA | Q04206 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aglafolin SCHEMBL18835920 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL748617 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL31581665 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL20496142 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL29369253 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL2629398 | 0.94 | EIF4A1 (0.88) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL23226910 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL19666138 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL18836234 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL23463149 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404088-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120238766-A1 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-09-20 | — | — | US | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110065786-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | TRUSTEES OF BOSTON UNIVERSITY | 2011-03-17 | — | — | US | disclosed |
| US-7816544-B2 | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816544-B2 | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | TRUSTEES OF BOSTON UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | NFKBIA, NFKB1, NFE2L2 | EIF4A1 4735/4885CYP3A4 423/4885HIF1A 1829/4885 |
| US-20120238766-A1 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | NFKBIA, NFKB1, NFE2L2 | EIF4A1 4735/4885CYP3A4 423/4885HIF1A 1829/4885 |
| US-20110065786-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | NFKBIA, NFE2L2, NFKB1 | EIF4A1 4015/4885CYP3A4 105/4885HIF1A 1160/4885 |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | NFKBIA, NFE2L2, NFKB1 | EIF4A1 4015/4885CYP3A4 105/4885HIF1A 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.